Spherix Network News Today

Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME...

Data from Spherix Global Insights second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan),...

Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market...

EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical

Earlier screening will be needed in the age of biomarkers....

Navigating the landscape of Wet AMD Therapies During AMD Awareness Month...

EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld

Exton, PA, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages...

Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the

Gene therapies and LRRK2 inhibition are at the forefront of prescribers interest, highlighting the need for a truly disease modifying therapy....